Director at $IMA Purchases 16,000 Shares as Insider Transaction

A recent insider trading activity at $IMA revealed that Joseph P Slattery, a director at the company, purchased 16,000 shares on December 24, 2025, totaling approximately $95,840. Quiver Quantitative reported this transaction based on data from a recent SEC filing. This purchase increased Slattery’s holdings of this class of stock by an undisclosed percentage, making his current total ownership of $IMA stock stand at 16,000 shares.

Over the past six months, insider trading activity at $IMA has occurred three times. All three of these trades were purchases, with a total of 367,167 shares bought. Notably, there have been no sales by insiders during this period. Some of the notable recent transactions include Otello Stampacchia’s purchase of 267,556 shares for approximately $7,999,924, and David P Bonita acquiring 83,611 shares for an estimated $2,499,968 in addition to Joseph P Slattery’s 16,000 share purchase.

The hedge fund activity surrounding $IMA has seen 32 institutional investors adding shares of the company to their portfolios in the most recent quarter. None of the institutions have decreased their positions during this time. Among the significant moves, Deep Track Capital, LP added 878,516 shares, BVF INC/IL added 802,102 shares, and Blue Owl Capital Holdings LP acquired 540,924 shares. Also, Omega Fund Management, LLC, OrbiMed Advisors LLC, Atlas Venture Life Science Advisors, LLC, and Vanguard Group Inc made substantial additions to their portfolios.

Moving on to analyst ratings, Wall Street has issued recent reports on $IMA, with one firm rating it as a buy and another as a sell. Specifically, Wedbush issued an “Underperform” rating on November 25, 2025, and Leerink Partners provided an “Outperform” rating on October 24, 2025. Analysts have varied opinions on the future performance of $IMA, which could impact investor decisions.

Multiple analysts have set price targets for $IMA in recent months, with a median target of $16.0. Notable targets include Martin Fan from Wedbush, who set a target price of $2.0 on November 25, 2025, and David Risinger from Leerink Partners, who set a target price of $30.0 on October 24, 2025. These price targets are based on analysts’ evaluation of $IMA’s potential growth and performance in the market.

In conclusion, insider trading activity and hedge fund transactions at $IMA, coupled with analyst ratings and price targets, provide valuable insights for investors considering their positions in the company. It is essential to conduct thorough research and due diligence before making investment decisions based on this information. Please note that this article is not financial advice and readers should refer to Quiver Quantitative’s disclaimers for further information.